What type of targeted drugs does Lapatinib/Talisat belong to?

Lapatinib (Lapatinib) is an oral, dual-target small molecule tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), which belongs to the category of HER2-targeted drugs. Different from traditional chemotherapy, lapatinib is designed to directly interfere with the signal transduction network inside cancer cells and inhibit its growth-driving mechanism at the molecular level. It acts on both HER2 (ErbB2) and EGFR (ErbB1) receptors, which play important roles in many malignant tumors, especially HER2-positive breast cancer.

Lapatinib competitively inhibits the binding of ATP to the HER2 and EGFR kinase domains and blocks downstream signaling pathways, such as PI3K/AKT and Ras/Raf/MAPK, thereby inhibiting cancer cell proliferation, promoting apoptosis and preventing tumor metastasis. Its "dual-target" design makes the efficacy more significant in tumors that are HER2-positive and accompanied by active EGFR signaling. This is different from the single-targeted antibody drug trastuzumab, whose site of action is limited to the extracellular region of the HER2 receptor, while lapatinib directly enters the cell interior and inhibits the signaling cascade from the source.

Due to its ability to penetrate the blood-brain barrier, lapatinib has unique value in the treatment of breast cancer brain metastases. Some studies have shown that lapatinib combined with the oral chemotherapy capecitabine may provide additional disease control benefits when patients are resistant to trastuzumab or have central nervous system metastases. Its small molecule characteristics make it an important supplementary method in anti-HER2 treatment, and also provides a typical example for the trend of oral targeting drugs.

In terms of pharmacological classification, lapatinib belongs to the second generation HER2/EGFR tyrosine kinase inhibitor and is one of the representative drugs for precision treatment. It is usually used as a second-line or third-line treatment for HER2-positive breast cancer in foreign guidelines, especially for patients who have received trastuzumab but whose disease still progresses. The emergence of lapatinib not only broadened the therapeutic spectrum of HER2-targeted drugs, but also promoted the development of dual-target inhibition strategies, which had a profound impact on the design of new-generation TKI drugs such as neratinib.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html